-
公开(公告)号：WO2008127271A3
公开(公告)日：2009-04-09
申请号：PCT/US2007019660
申请日：2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hTL-13活性有害的病症的人类受试者中。
-
公开(公告)号：WO2007117465A3
公开(公告)日：2008-08-28
申请号：PCT/US2007008307
申请日：2007-04-02
Applicant: ABBOTT LAB , ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
公开(公告)号：EP2064336A4
公开(公告)日：2010-03-17
申请号：EP07873427
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：EP2247310A4
公开(公告)日：2012-06-27
申请号：EP09708386
申请日：2009-01-29
Applicant: ABBOTT LAB
Inventor： ARGIRIADI MARIA A , BORHANI DAVID W , XIANG TAO , WU CHENGBIN , GHAYUR TARIQ
IPC: C07K1/30 , A61K39/395 , C07K16/24 , C30B7/00 , C30B29/58
CPC classification number: C30B29/58 , C07K1/306 , C07K16/244 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C30B7/00
-
公开(公告)号：EP2299821A4
公开(公告)日：2012-02-08
申请号：EP09763424
申请日：2009-06-09
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
IPC: A01N43/42 , C07D487/14 , C07D498/14 , C07D513/14
CPC classification number: C07D487/14 , C07D498/14 , C07D513/14
-
Patent Agency Ranking
公开(公告)号：EP2506716A4
公开(公告)日：2013-05-29
申请号：EP10835061
申请日：2010-12-01
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
IPC: C07D487/14 , A61K31/437 , A61K31/4985 , A61P19/00 , C07D471/14 , C07D498/14 , C07D513/14
CPC classification number: C07D487/14 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/14 , C07D498/14 , C07D513/14
-
公开(公告)号：EP2001480A4
公开(公告)日：2011-06-15
申请号：EP07754773
申请日：2007-04-02
Applicant: ABBOTT LAB
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/196 , A61P35/00 , C07D403/12
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
-
公开(公告)号：PE20140407A1
公开(公告)日：2014-04-25
申请号：PE2013001090
申请日：2009-06-09
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
IPC: C07D487/14 , A61K31/4985 , A61P35/00 , C07D498/14 , C07D513/14
Abstract: REFERIDA A UN COMPUESTO TRICICLICO DE FORMULA (I), DONDE T ES CR6, N, O, NR6, S; U ES N, CR4; X ES CR3, NR3; Y ES N O C; R1, R2 Y R5 SON H, HALOGENO, NO2, CN, ENTRE OTROS; R3 ES H, CICLOALQUILO C5-C12, ARILO C6-C10, ENTRE OTROS; R4 Y R6 SON H, HALOGENO, CICLOALQUILO C5-C12, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-((3R,4R)-3-(6H-IMIDAZO[1,5-a]PIRROLO[2,3-e]PIRAZIN-1-IL)-4-METILPIPERIDIN-1-IL)-3-OXOPROPANONITRILO, 7-(5-METOXI-1-METIL-1H-INDOL-3-IL)-1-METIL-6H-IMIDAZO[1,5-a]PIRROLO[2,3-e]PIRAZINA, 1-CICLOHEXIL-6H-IMIDAZO[1,5-a]PIRROLO[2,3-e]PIRAZINA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INMUNOLOGICAS Y ONCOLOGICAS
-
公开(公告)号：CA2644910C
公开(公告)日：2014-01-28
申请号：CA2644910
申请日：2007-04-02
Applicant: ABBOTT LAB
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
-
公开(公告)号：CR20120294A
公开(公告)日：2012-09-03
申请号：CR20120294
申请日：2012-05-30
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , BRENINLINGER ERIC C , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , MULLEN KELLY D , SOMAL GAGANDEEP , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
Abstract: Un compuesto con la Fórmula (Ia), (Ib), (Ic), (Id), (Ie), (Si), (Ig), (Ih), (Ii), (Ij), (Ik), o (Il), según se las define aquí, sales farmacéuticamente aceptables, prodrogas, metabolitos, estereoisómeros e isómeros de los mismos biológicamente activos, donde las variables se han definido aquí. Los compuestos de la invención son útiles para tratar condiciones inmunológicas y oncológicas.
-
-
-
-
-
-
-
-
-
Search Results
54
records
(took 0.02 seconds)
